Apini Therapeutics is a creating novel small chemical two most prevalent types of inflammatory bowel disease.
Apini Therapeutics has raised $2.4M in total funding. The most recent round was Seed. The last funding was announced in June 2025.
Apini Therapeutics's investors include Northern Gritstone, Syncona Partners LLP.
Apini Therapeutics is headquartered in Huntingdon, United Kingdom.
Apini Therapeutics is a creating novel small chemical two most prevalent types of inflammatory bowel disease.
Apini Therapeutics is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Apini Therapeutics — Funding & Investors." VCBacked, June 11, 2025, https://www.vcbacked.co/company/apini-therapeutics. Accessed August 13, 2026.
VCBacked. (2025). Apini Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/apini-therapeutics
{{cite web |title=Apini Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/apini-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated